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Abstract
Background: The purpose of this meta-analysis was to evaluate the clinical significance of diffusion-weighted
imaging in assessing the status of axillary lymph nodes in patients with breast cancer.
Methods: We searched the PubMed, Cochrane, and EMBASE databases, selected studies by inclusion and exclusion
criteria, and assessed the quality of selected studies. We explored the source of heterogeneity; calculated sensitivity,
specificity, positive and negative likelihood ratios, and pretest probability. A summary receiver operating
characteristic curve was performed. Student’s t test was used to compare the different mean apparent diffusion
coefficient values of different status lymph nodes.
Results: In selected 10 studies, a total of 801 patients and 2305 lymph nodes were included following inclusion
criteria. All scores of the quality assessment of the included studies were greater than or equal to 10 points.
The sensitivity was 0.89 (95 % CI 0.79–0.95), the specificity was 0.83 (95 % CI 0.71–0.91), the positive and negative
likelihood ratios were 3.86 (95 % CI 2.75–5.41) and 0.17 (95 % CI 0.09–0.32), the pretest probabilities were 53 and
54 %, the area under the curve were 0.93 (95 % CI 0.90–0.95), respectively. The mean apparent diffusion coefficient
value of metastatic lymph nodes was significantly lower than that of nonmetastatic axillary lymph nodes.
Conclusions: Diffusion-weighted imaging is a promising tool to discriminate between metastatic and
nonmetastatic axillary lymph nodes. Combined with the mean apparent diffusion coefficient value, it can
quantitatively diagnose lymph node metastases. Conducting large-scale, high-quality researches can improve the
clinical significance of diffusion-weighted imaging to distinguish metastatic and nonmetastatic axillary lymph nodes
in patients with breast cancer and provide the evidence to assess the status of axillary lymph nodes.
Keywords: Diffusion-weighted imaging, Apparent diffusion coefficient, Breast cancer, Axillary lymph node
metastases, Meta-analysis and systematic review
Background
Evaluating the status of axillary lymph nodes (ALNs) is
crucial in staging, deciding the treatment planning, and
predicting the long-term survival in breast cancer [1–3].
Biopsy is recognized as the gold standard for assessing
ALNs. However, the drawbacks of biopsy are high false
negative ratio result from sample errors and its invasive-
ness [4]. The imaging modalities for assessing the ALNs
are rapidly evolving. Ultrasound (US) is applied widely for
its convincing and dynamic observation. However, the
sensitivity and specificity of ultrasound for lymph node
metastasis were unreliable and controversial [5, 6].
Owing to radiation and relative lower diagnostic accur-
acy, computer tomography (CT) is limited in clinic [7].
Positron emission tomography (PET) and positron emis-
sion tomography/computed tomography (PET/CT) can
reflect metabolism of glycolytic activity. Undoubtedly,
they have shown the higher diagnostic significance in
assessing distant metastases and regional metastatic
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ALNs [8], but their high radiation and expensive fee
keep the common people away. Ultrasmall super para-
magnetic iron oxide (USPIO) is the same. Its satisfactory
performance was extinguished by drawbacks of time-
consuming, underlying risk and forbidden in clinical
practice [9].
Magnetic resonance imaging (MRI) is developing with an
unimaginable speed; over the past years, it has been used to
evaluate ALNs [10]. MRI can detect deep and contralateral
lymph nodes. Its sensitivity and specificity for metastatic
ALNs were higher than US and CT [11]. Diffusion-
weighted imaging (DWI) as an advanced technology of
MRI with its superior ability to apparent the diffusion of
water molecules freely in tissues [12] has also been useful
for diagnosing lymph nodes in the axillary and other sites.
Apparent diffusion coefficient (ADC) can quantify the dif-
fusion of water molecules; ADC value and ADC ratio were
applied to distinguish metastatic from nonmetastatic lymph
node widespread [13].
The role of DWI in diagnosing the metastatic ALNs
can be found in several published studies; however,
the existing results in these studies were enormously
varied, and a comprehensive systematic review would
be useful to synthesize the current available information.
Fig. 1 Flow chart: selection process of the studies
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Table 1 Characteristics of inclusion articles
















tp fp fn tn
Nakai 2011 Japan NG 16, 216 0, 800 1.5 NG 1.04 1.22 Cardiac surface Histopathologically 30 4 6 176
Kamitani 2012 Japan Retro 108, 110 0, 1000 1.5 1.05 1.08 0.92 Body Histopathologically 14 11 12 73
Fornasa 2013 Italy Prosp 43, 43 0, 800 1.5 1.09 0.88 1.4 4-channel
phased array
Histopathologically 18 2 1 22




138 498 4 602
800 1.35 1.18 1.55 134 376 8 724
Luo 2013 China NG 36, 79 0, 800 1.5 0.889 0.79 1.04 8-channel phased
array breast
Histopathologically 37 6 8 28
Chung 2013 South
Korea
NG 110, 110 0, 1000 1.5
3.0
0.9 0.69 1.04 4-channel phased
array breast
Histopathologically 68 26 22 136
Kim 2014 South
Korea
Retro 252, 253 0, 750 1.5 0.986 0.91 1.27 Bilateral breast surface Biopsy 69 26 22 136
Schipper 2014 Netherlands Prosp 50, 135 0, 500
800
3.0 0.65 0.72 0.75 32-channel cardiac
sensitivity encoding
Histopathologically 14 46 8 67
Yamaguchi 2014 Japan NG 16, 52 0, 800 1.5 0.852 0.75 1.03 Breast Biopsy 13 3 3 17
Razek 2015 Egypt Prosp 34, 65 0, 500
1000
1.5 1.30 1.08 1.15 8-channel breast Histopathologically 41 0 3 21












The aim of this meta-analysis was to assess the clin-
ical value of DWI in detecting ALN metastases in
patients with breast cancer.
Methods
Literature search
We searched studies about the diffusion-weighted im-
aging in diagnosing lymph node metastases in the
PubMed, EMBASE, and Cochrane library until May
2015 following the key words “diffusion-weighted,” “dif-
fusion weighted imaging,” “diffusion weighted magnetic
resonance imaging,” “DWI,” “lymph nodes,” “axillary,”
“breast cancer,” “breast carcinoma,” “ductal cancer,”
“tubular cancer,” and “medullar cancer”.
Inclusion and exclusion criteria
We reviewed studies for the following inclusion cri-
teria: (1) studies were published in English, (2) DWI
was performed in detecting ALNs with breast cancer,
(3) histopathological results were used as the refer-
ence standard, and (4) the true positive (TP), false
positive (FP), true negative (TN), and false negative
(FN) values can be calculated with sufficient data. We
excluded the studies with the following criteria: (1)
lack the explanations of DWI-detected ALNs with
breast cancer; (2) without histopathological reference
standard; (3) insufficient data to get the TP, FP, TN,
and FN values; (4) experimental subject was an ani-
mal and ex vivo; (5) the type of study was review,
case report, letter to editor, and meta-analysis; and
(6) unable to get the full text.
Data extraction and quality assessment
We extracted the following items in each study: author,
nation, publication year, sample size, b value, field
strength, the cutoff of ADC value, the mean ADC value
of the metastatic and nonmetastatic ALNs, study design,
and TP, FP, TN, and FN values.
Assessing studies through QUADAS [14], the total
score of the included studies must be greater than 10
points or equal to 10 points.
Statistical analysis
We applied Meta-DiSc version 1.4, Stata 12.0, SPSS 19.0,
to analyze data.
In order to assess the clinical significance of DWI, we
calculated sensitivity, specificity, positive and negative
likelihood ratios (PLR, NLR), and pretest probability and
performed a summary receiver operating characteristic
(SROC) curve based on the collected studies of TP, FP,
TN, and FN values.
Heterogeneity can affect the accuracy of estimation,
and I2 index was used to evaluate heterogeneity. There
was existing heterogeneity when P value was less than
0.05 and/or I2 value was over 50 % [15]. In diagnostic
meta-analysis, the threshold effect was considered as an
important source of heterogeneity. We used Spearman
correlation coefficient in Meta-DiSc version 1.4 to check
it. If threshold effect existed in our analysis, we summa-
rized receiver operating characteristic (ROC) curve and
calculated the area under the curve (AUC) directly. If no
threshold effect existed in our analysis, after calculating
the SROC and AUC, we also used meta-regression and
subgroup analysis to explore the source of heterogeneity
in Meta-DiSc version 1.4. We used Deeks’ funnel plot in
Stata 12.0 to assess publication bias [16].
Owing to the different mean ADC values in metastatic
and nonmetastatic ALNs, we used Student’s t test in




We total yielded 38 primary studies after searching the
PubMed, EMBASE, and Cochrane library. We excluded
17 studies after reading the title. From the remaining 21
studies, we excluded 11 studies after reading abstract or
full text and included 10 studies [13, 17–25]. The detail
of selection can be shown in Fig. 1.
Data extraction and study assessment
This study included a total of 801 patients and 2305
ALNs of the included 10 studies in this meta-analysis.
The detail characteristic data can be seen in Table 1. All
the selected studies were conducted with the QUADAS
Table 2 Results of the evaluation of each study according
to QUADAS-2
1 2 3 4 5 6 7 8 9 10 11 12 13 14 Score
Nakai + + + ? + + + + ? ? ? + + + 10
Kamitani + + + ? + + + + − ? ? + + + 10
Fornasa + + + + + + + + ? ? ? + + + 11
He + + + ? + + + + + ? ? + + + 11
Luo + + + ? + + + + ? ? ? + + + 10
Chuang + + + ? + + + + + + ? + + + 12
Kim + + + + + + + + ? + ? + + + 12
Schipper + + + + + + + + + ? + + + + 13
Yamaguchi + + + ? + + + + + ? ? + + + 11
Razek + + + + + + + + + ? ? + + + 12
+ = no bias; − = potential bias; ? = bias unclear; 1 = representative spectrum?;
2 = selection criteria clearly described?; 3 = acceptable reference standard?;
4 = time interval between MRI and pathology?; 5 = partial verification
avoided?; 6 = differential verification avoided?; 7 = incorporation avoided?;
8 = description execution of DW-MRI?; 9 = description execution of
pathology?; 10 = pathology results blinded?; 11 = DW-MRI results blinded?;
12 = clinical data available as in practice?; 13 = uninterpretable results
reported?; 14 = withdraw explained?
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test, and their scores were greater than 10 points or
equal to 10 points (Table 2).
Heterogeneity test
We evaluated heterogeneity through I2 index in Stata
12.0. We found P < 0.05 and I2 = 8.7 % indicating there
was existing heterogeneity in the included studies. We
used Spearman correlation coefficient in Meta-DiSc
version 1.4 to check threshold effect. We found that the
value of Spearman correlation coefficient was −0.064
and P = 0.852. We can confirm that threshold effect was
not the source of heterogeneity in this meta-analysis.
In order to assess the source of heterogeneity further,
we applied meta-regression (Table 3) and subgroup ana-
lysis by adding nation, design, b value, field strength, and
coil (Table 4). Meta-regression and subgroup analysis
showed that the source of heterogeneity cannot be found
in these factors (P > 0.05). However, among these stud-
ies, the heterogeneity was highly significant (I2 > 50 %).
Thus, we should interpret the results carefully.
Diagnostic performance of DWI and publication bias
The sensitivity, specificity, PLR, NLR, and the AUC of DWI
were 0.89 (95 % CI 0.79–0.95), 0.83 (95 % CI 0.71–0.91),
3.86 (95 % CI 2.75–5.41), 0.17 (95 % CI 0.09–0.32), and
0.93 (95 % CI 0.90–0.95), respectively (Figs. 2, 3, and 4).
Figure 5 shows that the post probability positive
(PPP) and post probability negative (PPN) were 86
and 13 %, respectively, when the pretest probabilities
were defined as 53 and 54 %.
As presented in Fig. 6, Deeks’ funnel plot indicated
that we found no significant publication bias among the
studies (P = 0.759).
The results of ADC values
We compared the mean ADC values of metastatic
and benign ALNs by Student’s t test. Figure 7
shows that the mean ADC value of metastatic ALNs
was significantly lower than that of benign ALNs
(P < 0.000).
Discussion
Diffusion-weighted MR is a noninvasive technique to
reflect functional information of tissues and is widely
used in diagnosing the malignant lesions. Recently,
detecting breast cancer and metastatic ALNs by DWI is
a hot spot. We desire to assess the clinical significance
of DWI in diagnosing metastatic ALNs in patients with
breast cancer through systemic review. We selected 10
studies following the included criteria. We got the high
sensitivity, specificity, and AUC as 89, 83, and 93 %,
respectively. The results demonstrated that DWI was a
promising method to differentiate diagnosis metastatic
from nonmetastatic ALNs.
We also calculated the PLR and NLR to assess the
performance of DWI. PLR and NLR are recognized as
the better parameters to test the diagnostic accuracy.
They can interpret one diagnostic tool through probabil-
ity. We can rule in a disease when the PLR > 10 and rule
out a disease when the NLR < 0.1 [26]. The PLR and
NLR were 3.86 (95 % CI 2.75–5.41) and 0.17 (95 % CI
Fig. 2 Forest plots of sensitivity and specificity with corresponding 95 % CIs of 18 studies. The pooled sensitivity and specificity were 0.89
(95 % CI 0.79–0.95) and 0.83 (95 % CI 0.71–0.91), respectively






Nation 0.594 0.868 0.513 1.81 (0.24~13.41)
Field strength −1.636 0.942 0.120 0.19 (0.02~1.71)
b value −0.266 1.275 0.838 0.77 (0.04~13.15)
Design 0.165 1.141 0.888 1.18 (0.08~16.38)
Coil −0.443 1.334 0.749 0.64 (0.03~15.07)
CI confidence interval
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0.09–0.32), respectively. The results indicated that DWI
could not rule in or rule out metastatic ALNs. Com-
bined with the PLR and NLR, DWI had an inferior
capacity to exclude or confirm metastatic ALNs. Fagan’s
nomogram was also used to estimate the probability of
having a disease in patients [27]. In this meta-analysis,
the pretest probabilities of a patient with suspected
metastatic ALNs were 53 and 54 %, and the posttest
probability positive and posttest probability negative
were 68 and 13 %, respectively, after likelihood ratio.
The results meant that the pretest probabilities of 53
and 54 % were the cutoff for DWI-diagnosed metastatic
Fig. 4 SROC curve for the diagnostic performance of DWI for all 10 studies combined. The pooled ROC with corresponding 95 % CI was 0.93
(95 % CI 0.90–0.95)
Fig. 3 Scattergram of the PLR and NLR. Pooled estimates for the DWI were as follows: PLR was 3.86 (95 % CI 2.75–5.41), and NLR was
0.17 (95 % CI 0.09–0.32). LLQ left lower quadrant, LRN negative likelihood ratio, LRP positive likelihood ratio, LUQ left upper quadrant, RLQ
right lower quadrant, RUQ right upper quadrant
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ALNs. We can confirm the metastatic ALNs in patient
when the pretest probabilities were higher than 53 and
54 % and excluded the metastatic ALNs in patient when
the pretest probabilities were lower than 53 and 54 %.
Therefore, the performance of DWI in differential
diagnosis between metastatic and benign ALNs needs
to be lucubrated.
ADC derived from DWI can determine the malignant
lesions quantitatively and excluded the effect of T2 shine
through [28]. Brownian motion of water molecules in
cells can be quantitatively reflected. Wang et al. [29]
found that the density of ALNs had significant positive
correlation with metastatic lymph nodes and had signifi-
cant negative correlation with ADC value. It meant that
the diffusion of metastatic ALNs was higher than that of
the benign ones and the ADC value of metastatic ALNs
was lower than that of the benign ones. In Fig. 7, we
found that the mean ADC value of metastatic ALNs was
lower than that of the benign ones (P < 0.000). However,
Xue et al. [30] and Roy et al. [31] got the opposite
results. Actually, owing to the different selected ROI
[32], liquefied active necrosis [33], and inflammatory
and fibrous connective tissue proliferation [29], we
acknowledged that certain overlap existed in metastatic
and benign lymph nodes. In order to avoid the overlap,
applying ratio of lymph node ADC value to primary
tumor ADC value [34] and relative ADC values [35] may
be a better method for detecting lymph node metastasis.
Therefore, the clinical significance of different kinds of
ADC values has more perspective. In this meta-analysis,
we also found that the cutoff of diagnosing metastatic
ALNs were variable and had no statistical significance.
Interestingly, in previous animal research [29], they
found that the effect of perfusion can be ignored with
b value ≥1000 and the diagnostic performance was
better than that of the low b value. Previous study
also demonstrated that with higher b value, the more accur-
acy the ADC had in other tumor [36]. Combined with
Fig. 5 Posttest probabilities were calculated in Fagan’s nomograms by using different pretest probabilities of ALN metastases. The left, middle,
and right parts represented the 53 and 54 % pretest probabilities
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professional knowledge, b value may be one of the sources
of heterogeneity. In selected studies, the diagnosis perform-
ance with high b value was higher than with the lower ones
(Table 4). However, with a low b value, owing to the perfu-
sion effect, water diffusion motion cannot be reflected
accurately. Moreover, the risk of distortion and suscepti-
bility artifacts existing in DWI with high b value also
cannot be ignored [37]. Different b values can affect the
measurement of ADC and cutoff of ADC. It is necessary to
get optimal b value for us to assess the statues of ALNs.
Unifying the parameters of scan, cutoff of ADC, and opti-
mal b value and improving spatial resolution were the dir-
ection of DWI in diagnosing ALN metastases in the future.
We should acknowledge the limitations of this meta-
analysis. First, with the limited number of selected
studies, we cannot find the source of heterogeneity.
Fig. 7 Box plot showed the comparison of the mean ADC value of metastatic and nonmetastatic ALNs. The mean ADC value of metastatic ALNs
was significantly lower than that of the nonmetastatic ones (P < 0.000)
Fig. 6 Deeks’ funnel plot indicated no publication bias (P = 0.759)
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Table 4 The results of subgroup analysis
Variable Number Pooled sensitivity I2 (%) Pooled specificity I2 (%) Positive likelihood ratio Negative likelihood ratio Diagnostic odds ratio
Retrospective 3 0.729 (0.664–0.789) 60.2 % 0.846 (0.807–0.879) 0.0 4.628 (3.627–5.904) 0.350 (0.239–0.514) 14.358 (9.519–21.655)
Prospective 7 0.898 (0.860–0.929) 78.8 % 0.625 (0.600–0.650) 97.1 6.152 (2.387–15.857) 0.156 (0.072–0.342) 43.259 (10.752–174.0)
Field strength (1.5 T) 8 0.841 (0.806–0.872) 85.0 % 0.678 (0.655–0.699) 97.1 6.513 (2.884–14.711) 0.195 (0.12–0.314) 31.716 (15.746–63.884)
Field strength (3.0 T) 2 0.732 (0.640–0.811) 18.2 % 0.738 (0.682–0.789) 95.2 2.716 (0.874–8.438) 0.409 (0.197–0.849) 6.644 (1.086–40.634)
b value <1000 (s/mm2) 8 0.867 (0.831–0.899) 82.0 % 0.646 (0.6239–0.669) 97.1 5.801 (2.575–13.066) 0.177 (0.09–0.323) 35.007 (12.019–101.96)












Second, the potential publication bias could not be
ignored, although our result showed no significant
publication bias. Third, lacking enough high-quality
prospective studies may uncover the ability of DWI
detecting the metastatic ALNs.
In conclusion, DWI is a promising diagnostic method
for differentiation between benign and metastatic ALNs.
ADC value can quantitatively analyse ALNs. Larger
number of high-quality prospective studies regarding
DWI and ADC to detect ALN metastases still need to
be performed.
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